Adicet Bio, Inc. · NASDAQ:ACET
Adicet Bio — resTORbio — Technical Presentation (July 2018)
19 slides from Adicet Bio's technical presentation, Jul 25, 2018
Slide 1: RTB101 Phase 2b Topline Data
July 25, 2018 RTB101 Phase 2b Topline Data Exhibit 99.2
Slide 2: Forward-looking statements
This presentation may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the safety, efficacy and regulatory and clinical progress of our product candidates, including RTB101 alone and i
Slide 3: TORC1 is an evolutionarily conserved pathway that regulates aging
TORC1 is an evolutionarily conserved pathway that regulates aging Improved Immune Function Ameliorate Heart Failure Ameliorate Neurodegenerative Diseases TORC1 inhibition extended lifespan and healthspan and improved the following aging-related conditions in preclinical studies: Mice Flies Worms Yea
Slide 4: TORC1 inhibitors improved immune function in the elderly in two previous Phase 2a trials
TORC1 inhibitors improved immune function in the elderly in two previous Phase 2a clinical trials
Slide 5: Positive topline results in Phase 2b trial of RTB101
Positive topline results in Phase 2b trial of RTB101 Statistically significant and clinically meaningful 30.6% reduction in the percentage of patients with one or more laboratory-confirmed respiratory tract infections (RTIs), the primary endpoint of the trial, in the RTB101 10 mg once daily cohort (
Slide 6: Phase 2b clinical trial design
Phase 2b clinical trial design Primary Endpoint: Reduction in the percentage of patients with laboratory-confirmed RTIs through week 16 Population: Elderly subjects at increased risk of RTI-associated morbidity and mortality including: ≥ 85 years of age 65-84 years of age with one or more of the fol
Slide 7: Demographics
Demographics Part 1 Part 2 Parameter Statistics RTB101 5mg (N=61) RTB101 10mg QD1 (N=58) Placebo (N=60) Total (N=179) RTB101 10mg QD (N=118) RTB101 10mg BID2 (N=120) RTB101 + everolimus (N=115) Placebo (N=120) Total (N=473) Age at Randomization (Year) n 61 58 60 179 118 120 115 120 473 Mean (SD) 74.
Slide 8: Significant reduction in laboratory-confirmed RTIs in the once daily cohort
A significant reduction in the percentage of patients with laboratory-confirmed RTIs was observed in the RTB101 10 mg once daily cohort -20.6% 8.5% 8.5% -30.6% RTB101 5mg QD (n=61) RTB101 10mg QD (n=176) RTB101 10mg BID (n=120) RTB101 10mg + everolimus 0.1mg (n=115) P-value1 0.108 0.026 0.617 0.694
Slide 9: Pre-specified subgroup analyses of RTI reduction
Pre-specified analyses of laboratory-confirmed RTI reduction in patient subgroups treated with RTB101 10 mg once daily 85+ (n=27) Asthma (n=46) T2DM (n=86) Non-COPD (n=131) P-value1 0.007 0.0002 0.020 0.002 0.001 Odds ratio2 (CI3) 0.182 (0.059; 0.564) 0.110 (0.040; 0.305) 0.337 (0.141; 0.806) 0.317
Slide 10: Preclinical data: mTOR inhibition in asthma and smoking models
Preclinical data: mTOR inhibition decreased airway inflammation in asthma and increased airway inflammation due to smoking Asthma Smoking mTOR inhibition with rapamycin (Rapa) significantly decreased airway inflammation in a preclinical asthma model in which mice were exposed to intranasal house dus
Slide 11: Safety and tolerability
Safety and tolerability Adverse events (AEs) were balanced between the RTB101 10 mg once daily and placebo cohorts 1 unrelated death occurred in the RTB101 10 mg once daily cohort (patient was hit by car while riding a bicycle), 1 unrelated death occurred in the placebo cohort (unknown cause) 4.5% o
Slide 12: Consistent efficacy of once daily observed in two Phase 2 trials
Consistent efficacy of RTB101 10 mg once daily observed in two Phase 2 clinical trials enrolling more than 900 elderly people Phase 2a (n=264) 23% with comorbidities 42%**RTIs 47%RTIs in asthma patients No subjects ≥ 85 years of age in placebo ✓ ✓ Phase 2b (n=652) 100% with comorbidities 31%* RTIs 6
Slide 13: Summary of 16-week analysis of Phase 2b
Summary of 16-week analysis of Phase 2b There was a statistically significant and clinically meaningful reduction in the percentage of patients with one or more laboratory-confirmed RTIs, the primary endpoint of the study, in the RTB101 10 mg once daily cohort RTB101 10 mg twice daily and RTB101 10
Slide 14: Medical Need & Market Opportunity
Medical Need & Market Opportunity
Slide 15: RTIs represent a significant healthcare burden
RTIs are the 4th most common cause for hospitalization in 65+1 (2nd in 85+1) RTIs are the 7th leading cause of death in 65+2 (5th in 85+2) RTIs are the leading cause of asthma exacerbations3 RTIs represent a significant healthcare burden 1Pfunter, A (2013) HCUP Statistical Brief #162; 2Kochanek KD,
Slide 16: Estimated 75 million elderly people at increased risk of RTIs
US EU5 JP Elderly people (65-74 years old): With comorbidities (COPD, asthma, T2DM, CHF) 11M 13M 7M Elderly people (75-84 years old): With comorbidities (COPD, asthma, T2DM, CHF) 7M 11M 6M Elderly people (85+ years old): 6M 9M 5M # Elderly People (2016) 24M 33M 18M Average Annual Growth Rate 3% 2% 1
Slide 17: Physician survey: expected use in target populations
% Reduction in RTI Estimated % prescribed in aged 85+ or 65+ with comorbidities, patient-weighted 25% >30% 33% >40% 40% >45% Survey of 100 physicians to determine potential usage in the target patient populations Medical Specialty Geriatrics 25 Primary Care 50 Pulmonologist 25 Practice characteristi
Slide 18: Near term planned clinical milestones and path forward
Q1 Q2 Q3 Q4 H1 H2 Near term planned clinical milestones and path forward Ph 2b Topline Data Initiation POC clinical study 2nd indication Initiation of POC clinical study 3rd indication Pivotal Trial Initiation 2018 2019 Second Ph 2a Publication Ph 2b 24 week data Completed dosing all patients in Ph
Slide 19: RTB101 Phase 2b Data Review
July 2018 RTB101 Phase 2b Data Review